Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors

Enguang Feng, Woo Jin Shin, Xuelian Zhu, Jian Li, Deju Ye, Jiang Wang, Mingyue Zheng, Jian Ping Zuo, Kyoung Tai No, Xian Liu, Weiliang Zhu, Wei Tang, Baik Lin Seong, Hualiang Jiang, Hong Liu

Research output: Contribution to journalArticlepeer-review

49 Citations (Scopus)


In order to exploit the 430-cavity in the active sites of neuraminidases, 22 zanamivir analogs with C-1 and C-4 modification were synthesized, and their inhibitory activities against both group-1 (H5N1, H1N1) and group-2 neuraminidases (H3N2) were determined. Compound 9f exerts the most potency, with IC50 value of 0.013, 0.001, and 0.09 μM against H3N2, H5N1, and H1N1, which is similar to that of zanamivir (H3N2 IC50 = 0.0014 μM, H5N1 IC50 = 0.012 μM, H1N1 IC50 = 0.001 μM). Pharmacokinetic studies of compound 9f in rats showed a much longer plasma half-life (t1/2) than that of zanamivir following administration (po dose). Molecular modeling provided information about the binding model between the new inhibitors and neuraminidase, with the elongated groups at the C-1-position being projected toward the 430-loop region. This study may represent a novel starting point for the future development of improved antiflu agents.

Original languageEnglish
Pages (from-to)671-684
Number of pages14
JournalJournal of Medicinal Chemistry
Issue number3
Publication statusPublished - 2013 Feb 14

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors'. Together they form a unique fingerprint.

Cite this